Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,186.00
Bid: 12,186.00
Ask: 12,190.00
Change: 90.00 (0.74%)
Spread: 4.00 (0.033%)
Open: 12,150.00
High: 12,266.00
Low: 12,134.00
Prev. Close: 12,096.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WRAPUP 1-Euro zone economies' plucky Q4 belies troubled growth outlook

Fri, 29th Jan 2021 11:37

* Germany and Spain eke out narrow Q4 growth

* France contracts by less than expected

* But vaccine roll-out issues, restrictions blight outlook

* IMF sees euro zone recovery lagging U.S., Japan

By Paul Carrel and Leigh Thomas

BERLIN/PARIS, Jan 29 (Reuters) - Growth in Germany and Spain
and a smaller-than-expected contraction in France pointed to
resilience in the euro zone economy in the final three months of
last year, but the bright spot belies a more troubled outlook
for the bloc.

In Germany, robust exports helped Europe's largest economy
eke out 0.1% growth in the fourth quarter, staving off
contraction despite a second wave of the new coronavirus
slamming the brakes on consumption, data showed on Friday.

France, the euro zone's second-largest economy, shrank 1.3%
in the final three months of 2020 after the country entered a
second coronavirus lockdown in October to contain a second wave
of infections.

Spain achieved timid quarterly growth of 0.4%. But that has
not stopped Spain from recording its worst-ever annual economic
contraction, with output falling 11% from 2019's level, official
data showed.

"Numbers for Germany, France and Spain showed that GDP was
relatively resilient in Q4," Nicola Nobile at Oxford Economics
wrote in a research note. But he added, "there are not many
indications that this dynamic could have continued in Q1."

"All in all, the disappointing vaccine roll-out so far, the
extension of restrictions in many European countries and the
latest data now point to continued weakness in the eurozone over
the coming months."

The French slump, which followed an 18.5% rebound in the
third quarter after a first lockdown, beat expectations for a 4%
contraction on average in a Reuters poll of 28 economists,
surpassing even the highest estimate of -1.4%.

But France is on tenterhooks to find out in the coming days
whether the government will put the country under a new lockdown
and in particular whether schools will be closed.

In Germany, Chancellor Angela Merkel and state leaders
agreed last week to extend a lockdown until mid-February as the
country, once a role model for fighting the pandemic, struggles
with a second wave and record daily numbers of COVID-19 deaths.

On Wednesday, German government slashed its growth forecast
to 3% this year, a sharp revision from last autumn's estimate of
4.4%, caused by a second coronavirus lockdown.

TRAILING U.S.

The economic outlook across the 19-country euro zone is
being muddied by a row between the European Union and
Anglo-Swedish firm AstraZeneca over its supply of
vaccines to the bloc, and by the return of inflation in Germany.

The International Monetary Fund said this week the euro area
is likely to slip behind the United States in its recovery.

"Recovery paths vary within the group, with the U.S. and
Japan projected to regain end-2019 activity levels in the second
half of 2021, while in the euro area and the United Kingdom
activity is expected to remain below end-2019 levels into 2022,"
the IMF said in its in its World Economic Outlook.

The AstraZeneca supply issue is a blow to Europe's COVID-19
vaccination drive, and the German inflation spike - consumer
prices turned positive and rose in January to 1.6% on the year -
adds to a complex mix of data for the European Central Bank to
assess.

ECB data released on Friday showed lending to euro zone
companies picked up last month though the bloc was probably back
in recession and banks said they were tightening access to
credit amid fear of defaults amid a fresh wave of lockdowns.

The ECB is unlikely to cut its already-record-low policy
because that would do little to revive the pandemic-hit euro
zone economy, five sources told Reuters, playing down concern
about a strong euro.

Traders were left scratching their head this week when Dutch
central bank governor Klaas Knot said the ECB "had room" to push
its Deposit Facility Rate, currently at minus 0.5%, further
below zero if needed to stem a rally in the euro EUR=.

The sources said Knot had raised the rate cut issue at the
ECB's policy meeting last week but the discussion was "marginal"
and not considered part of the ECB's policy strategy, which is
now focussed on bond purchases and cheap loans to banks.

"ECB communication could be such a powerful tool but is
really very confusing," BofA analysts said in a research note.

(Additional reporting by Belén Carreño and Joao Manuel Vicente
Mauricio in Madrid and by Francesco Canepa, Balazs Koranyi and
Frank Siebelt in Frankfurt; editing by Larry King)

More News
27 Dec 2023 08:24

TOP NEWS: AstraZeneca buys Gracell to "enrich" cell therapy pipeline

(Alliance News) - AstraZeneca PLC on Tuesday said it has agreed to acquire Gracell Biotechnologies Inc, paying about USD1.2 billion for the clinical-stage company.

Read more
27 Dec 2023 07:52

LONDON BRIEFING: AstraZeneca buys Gracell Biotech; COPL CEO resigns

(Alliance News) - Stocks in London were expected to make gains at Wednesday's market open, as investors continued to pin their hopes on US interest rate cuts.

Read more
27 Dec 2023 07:02

AstraZeneca to buy Gracell Technologies for $1.2bn

(Sharecast News) - AstraZeneca on Wednesday said it was buying Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, for $1.2bn.

Read more
26 Dec 2023 21:26

Wall Street ends higher in final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
26 Dec 2023 21:00

Wall Street ends higher in final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
26 Dec 2023 19:41

Wall Street gains on final stretch of 2023, rate cuts in view

Intel up on $3.2 bln grant from Israel

*

Read more
22 Dec 2023 08:47

AstraZeneca, Ionis get US FDA nod for Wainua in "important milestone"

(Alliance News) - AstraZeneca PLC and Ionis Pharmaceuticals Inc on Friday celebrated the news that their drug eplontersen was approved by the US Food & Drug Administration.

Read more
22 Dec 2023 07:50

LONDON BRIEFING: UK on brink of recession as economy contracts in Q3

(Alliance News) - Stocks in London are likely to open lower on Friday, with investors feeling frosty ahead of a US inflation print this afternoon, amid sobering UK economic growth data.

Read more
22 Dec 2023 07:17

AstraZeneca gets FDA green light for nerve disease treatment

(Sharecast News) - The US Food and Drug Administration has approved the Wainua nerve disease treatment jointly developed by AstraZeneca and Ionis Pharmaceuticals.

Read more
19 Dec 2023 19:56

US adds 13 companies in China to Unverified List

WASHINGTON, Dec 19 (Reuters) - The United States has added 13 companies in China to a list of entities receiving U.S. exports that officials have been unable to inspect, according to a government notice posted on Tuesday.

Read more
15 Dec 2023 17:14

London stocks log weekly gains as cenbank fest ends

FTSE 100 down 1.0%, FTSE 250 off -0.3%

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
13 Dec 2023 17:07

UK's FTSE 100 rises as pound slips on GDP data; awaits Fed rate decision

UK economy shrinks by 0.3% in October

*

Read more
12 Dec 2023 16:00

London close: Stocks slip as investors digest US inflation

(Sharecast News) - London's markets finished in the red on Tuesday, as investors digested a slight decrease in consumer inflation in the US, while the UK's unemployment figures remained stable.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.